News Conference News Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices L.A. McKeown November 18, 2022
News Conference News VIVA 2022 ‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups L.A. McKeown November 04, 2022
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Daily News NSTEMI Patients With CKD: Early Invasive vs Delayed Strategy Similar for Survival Caitlin E. Cox October 03, 2022
News Conference News TCT 2022 Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL Yael L. Maxwell September 19, 2022
News Daily News Worse Complications After PVI in Women Highlight Research Gaps L.A. McKeown August 16, 2022
News Daily News IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document L.A. McKeown August 05, 2022
News Daily News Longer-Term Data Still Worrisome for Impella-Treated AMICS Patients Caitlin E. Cox July 20, 2022
News Industry News Robocath’s Joint Venture, Cathbot, Concludes First Clinical Study in China to Evaluate Robotic PCI Safety and Efficacy July 20, 2022
News Daily News PFO Closure in Adults Over 60 Safe, but Patient Selection Key Yael L. Maxwell July 01, 2022
News Daily News Comorbidities May Drive PAD Procedural Outcomes in Black Patients L.A. McKeown June 23, 2022
News Daily News Contrast Shortage Offers Lessons for Improving Value-Based Care Todd Neale June 21, 2022
News Daily News Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy L.A. McKeown June 01, 2022
News Conference News EuroPCR 2022 Imaging in PCI for Patients at High Bleeding Risk: Data Point to Possibilities Caitlin E. Cox May 25, 2022
News Conference News SCAI 2022 DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year L.A. McKeown May 23, 2022
News Daily News SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement L.A. McKeown April 27, 2022
News Daily News Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities Michael O'Riordan April 25, 2022